Merck KGaA, Darmstadt, Germany Selects Cambridge Semantics as Enterprise Data Fabric Provider
16.7.2020 15:00:00 EEST | Business Wire | Press release
Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its data fabric provider.
Through this multi-year agreement, Cambridge Semantics will help Merck KGaA, Darmstadt, Germany establish an enterprise data fabric to support multiple data management initiatives. Cambridge Semantics’ Anzo® platform will enable Merck KGaA, Darmstadt, Germany to deliver on immediate data-driven requirements, including regulatory compliance with Identification of Medicinal Products (IDMP), while establishing a future-proof data strategy by driving further value from data and analytics.
“New regulatory requirements necessitate innovative approaches to data management,” said Jörg Werner, Associate Director Regulatory Data Governance at Merck KGaA, Darmstadt, Germany. “We selected Cambridge Semantics over other software vendors because Anzo’s underlying technology, which is based on semantics graph data models, aligns well with our data strategy to integrate and access information across research and development.”
Cambridge Semantics and Merck KGaA, Darmstadt, Germany delivered the first production solution in December 2019 focused on harmonizing and standardizing terminologies for regulatory compliance. The teams are now partnering to expand the regulatory data fabric with data from several legacy systems to provide unprecedented and comprehensive access to regularly data objects and accelerate its strategic Veeva implementation.
Cambridge Semantics’ Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization’s data is highly distributed, vastly siloed, complex and when users want answers to unanticipated questions at scale and speed.
Moritz Kloft, IT Product Manager at Merck KGaA, Darmstadt, Germany added, “While we had multiple platform choices, including several based on semantics and ontology, only Cambridge Semantics has the technology, team and vision to deliver an enterprise-scale platform to support our data-driven research and development roadmap.”
“The pharmaceutical industry faces some of the most complex, critical and broad data challenges and requirements affecting business today, and it’s an industry in which having the right data can save lives,” said Chuck Pieper, Chairman and Chief Executive Officer at Cambridge Semantics. “We are incredibly proud that Merck KGaA, Darmstadt, Germany has selected Cambridge Semantics as their data management partner. We are confident that the work we do together will be transformative in building a rich data fabric and gathering new insights that Merck KGaA, Darmstadt, Germany can use for decision-making across R&D.”
Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics added, “The scale and rich history of innovation in technology R&D of Merck KGaA, Darmstadt, Germany offers the limitless potential to realize and expand our vision for the enterprise data fabric. We look forward to advancing our product roadmap and Europe-based service offerings in support of data integration and analytics initiatives of Merck KGaA, Darmstadt, Germany.”
About Cambridge Semantics
Cambridge Semantics Inc. is a modern, graph-driven data integration and analytics software company that enables seamless access to all enterprise data. Cambridge Semantics was recently recognized as a leader in Forrester Research’s Enterprise Data Fabric Wave.
The company delivers products and solutions that enable IT departments and business users across Life Sciences, Healthcare, Financial Services, Government, Manufacturing, and other industries to accelerate data delivery and to provide meaningful insights across the organization at speed and scale.
Cambridge Semantics is based in Boston, Massachusetts.
For more information visit www.cambridgesemantics.com or follow us on Facebook, LinkedIn, and Twitter: @CamSemantics.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the rights to the name and trademark “Merck” internationally except for the United States and Canada, where it operates in the biopharma market as EMD Serono, in life science as MilliporeSigma, and in the specialty chemicals and high/tech materials business area as EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005180/en/
Contact information
Lora Wilson / Valerie Christopherson
Global Results Communications for Cambridge Semantics
cambridge@globalresultspr.com
+1 (949) 608-0276
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom